HCA Healthcare faced several rating downgrades and financial outlook revisions throughout July. Barclays lowered its rating while Wells Fargo reduced its price target due to uncertainties surrounding patient volumes. The company also cut its 2026 EPS guidance to a range of $28.70–$30.50, citing persistent policy pressures, an increase in uninsured patients, and shifts in the payer mix.
As markets anticipate second-quarter results, HCA Healthcare is facing heightened uncertainty driven by rising operating expenses and a decline in outpatient surgery volumes.
Read the full storyAnalysts upgrade the largest US hospital operator to 'Buy' following a price slump, noting that current valuations now reflect policy and payer mix headwinds.
Barclays shifts HCA to Equalweight, citing risks from Medicaid funding cuts and shifting payer mixes ahead of the company's upcoming Q2 earnings report.